Azevan Pharmaceuticals
Bethlehem, United States· Est. 2003
A clinical-stage drug development company advancing first-in-class, orally bioavailable vasopressin 1a receptor (V1aR) antagonists for stress-related CNS disorders, traumatic brain injury (TBI), and neurodevelopmental diseases
Private Company
Total funding raised: $3.7M
About
A clinical-stage drug development company advancing first-in-class, orally bioavailable vasopressin 1a receptor (V1aR) antagonists for stress-related CNS disorders, traumatic brain injury (TBI), and neurodevelopmental diseases
Small Molecules
Funding History
2Total raised:$3.7M
Grant$2.2MSep 15, 2018
Grant$1.5MMay 15, 2016